Discloses use of i) an oligonucleotide which reduces clusterin expression and ii) an androgen receptor antagonist having the structure as disclosed in the complete specification, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a mammalian subject afflicted with prostate cancer. Also discloses an oligonucleotide which reduces clusterin expression and an androgen receptor antagonist, in the manufacture of a medicament for the treatment of a mammalian subject afflicted with androgen-independent prostate cancer.
